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Abstract
Background: There is accumulating evidence that the activation of spinal glial cells, especially microglia, is a key event in
the pathogenesis of neuropathic pain. However, the inhibition of microglial activation is often ineffective, especially for
long-lasting persistent neuropathic pain. So far, neuropathic pain remains largely intractable and a new therapeutic strategy
for the pain is still required.
Methods/Principal Findings: Using Seltzer model mice, we investigated the temporal aspect of two types of neuropathic
pain behaviors, i.e., thermal hyperalgesia and mechanical allodynia, as well as that of morphological changes in spinal
microglia and astrocytes by immunohistochemical studies. Firstly, we analyzed the pattern of progression in the pain
behaviors, and found that the pain consisted of an ‘‘early induction phase’’ and subsequent ‘‘late maintenance phase’’. We
next analyzed the temporal changes in spinal glial cells, and found that the induction and the maintenance phase of pain
were associated with the activation of microglia and astrocytes, respectively. When Bushi, a Japanese herbal medicine often
used for several types of persistent pain, was administered chronically, it inhibited the maintenance phase of pain without
affecting the induction phase, which was in accordance with the inhibition of astrocytic activation in the spinal cord. These
analgesic effects and the inhibition of astrocytic activation by Bushi were mimicked by the intrathecal injection of
fluorocitrate, an inhibitor of astrocytic activation. Finally, we tested the direct effect of Bushi on astrocytic activation, and
found that Bushi suppressed the IL-1b- or IL-18-evoked ERK1/2-phosphorylation in cultured astrocytes but not the ATP-
evoked p38- and ERK1/2-phosphorylation in microglia in vitro.
Conclusions: Our results indicated that the activation of spinal astrocytes was responsible for the late maintenance phase of
neuropathic pain in the Seltzer model mice and, therefore, the inhibition of astrocytic activation by Bushi could be a useful
therapeutic strategy for treating neuropathic pain.
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Introduction
Neuropathic pain is the chronic pain state after a lesion or
disease of the peripheral or central nervous system such as bone
compression in cancer, diabetes, infection and acquired
immunodeficiency syndrome [1]. A common symptom of this
disease is mechanical allodynia, a painful response to innocuous
tactile stimuli, and a decrease in nociceptive thresholds to the
stimuli [2]. It has been reported that millions of people are
suffering from neuropathic/chronic pain in the world [3], but
most analgesics including non-steroidal anti-inflammatory drugs
(NSAIDs) and even opioids, lack satisfactory efficacy for
neuropathic pain [4], and they sometimes produce undesirable
side effects [5].
There has been a paradigm shift in the understanding of the
pathogenesis of neuropathic pain. Although neuropathic pain has
long been considered to be caused by relevant changes in neurons,
emerging lines of evidence have revealed that morphological and
functional changes also occur in spinal glial cells [6,7,8], especially
in microglia, the immune cells in the CNS [2,3,9,10,11,12]. After
peripheral nerve injury, microglia change their shapes and
characteristic features from ‘resting’ to ‘activated’ through a series
of cellular and molecular changes. Such activated microglia
produce several diffusible molecules such as BDNF, by which
microglia alter the excitability of adjacent neurons in the dorsal
horn, leading to tactile allodynia [13]. Therefore, pharmacological
and genetic manipulations of microglial functions could be a useful
strategy for the control of neuropathic pain. Minocycline, an
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neuropathic pain, but importantly, it often fails to suppress existing
or established neuropathic pain [14,15], suggesting a limited role
of microglial activation in the neuropathic pain.
In addition to microglia, there is accumulating evidence that
spinal astrocytes also change their morphology and function in the
pathology of neuropathic pain, suggesting their involvement in
neuropathic pain [16,17]. Astrocytes directly alter neurotransmis-
sion because they encapsulate synapses and are in close contact
with neuronal somas [18]. Importantly, changes in the astrocytic
activities are known to dynamically alter the efficacy of
neurotransmission in both physiological and pathological condi-
tions [19,20,21], suggesting a possible linkage between astrocytic
activation and neuropathic pain. In some cases, suppression of
astrocytic activation by the astrocyte toxin, fluorocitrate, leads to
an analgesic effect for neuropathic pain in several types of models
[22,23,24]. Thus both microglia and astrocytes seem to be
involved in neuropathic pain, but the temporal patterns of their
activations are completely different, i.e., CD11b, a microglia
specific complement receptor 3, is upregulated earlier whereas
GFAP, an astrocyte specific intermediate filament, is upregulated
later after the nerve injury [23]. Microglia upregulate interleukin
(IL)-18 in the early induction phase, by which astrocytes are
activated in the late maintenance phase of tactile allodynia [25].
After nerve injury, microglia are activated by MMP-9-cleaved IL-
1b in the early pain phase, which is followed by astrocytic
activation induced by MMP-2-cleaved IL-1b in the later phase
[26]. Based on these reports, microglia and astrocytes are likely to
have distinct roles in the pathology of neuropathic pain. However,
little is known about differences in the temporal pattern of
activation in each type of glial cell, or differences related to the
progression or maintenance the neuropathic pain. In addition, so
far, there is no available medicine can selectively inhibit each type
of glial cells to reveal analgesic effect.
Although neuropathic pain is generally considered a refractory
disease [4], some herbal medicines are known to be effective for
such pain. Herbal medicines and acupuncture [27] have attracted
worldwide attention for chronic pain relief. Japanese herbal
medicine, known as Kampo, was originally based on Chinese
herbal medicine, but has developed independently and is a
standardized form of herbal medicine or remedy in terms of the
quality and quantities of the ingredients. Similar to Western
medicine, the quality and quantities of ingredients are strictly
controlled, and many of them are often used for several types of
diseases [28,29]. Among herbal medicines, we focused on Bushi
(TJ-3023, Tsumura, Japan), which is derived from aconite and is
contained in several Kampo medicines such as Gosha-jinki-gan,
Hachimi-jio-gan and Shinbu-to. They are known to be effective
for streptozotocin-induced diabetic autonomic neuropathy [30],
paclitaxel-induced peripheral neuropathy [31] and some other
types of pain [32,33]. In addition and more importantly, Bushi has
been effective for several types of chronic and persistent pain
including neuropathic pain and, is therefore, often used for such
patients in our university hospital (Univ. Yamanashi Hospital,
personal communication). Although the analgesic effect of herbal
medicine is well documented, little is understood about its
biological basis. Thus, elucidation of the molecular mechanism(s)
underlying the analgesic effect of Bushi contributes to understand-
ing the pathology of neuropathic pain and, in addition, it could
provide important clues to a new strategy of medical treatment.
In the present study, we show that neuropathic pain consists of
the microglia-mediated early induction phase and the subsequent
astrocyte-mediated maintenance phase in Seltzer model mice, and
demonstrate that Bushi exerts its analgesic effect against the
maintenance phase of neuropathic pain by inhibiting the
activation of astrocytes but not microglia.
Results
Effects of Bushi on pain behaviors and spinal glial
activation in Seltzer model mice
Throughout the experiments, we used Seltzer model mice
[sciatic nerve ligation (SNL)-mice] as a neuropathic pain model.
Bushi was orally administered to SNL-mice (SNL-Bushi) and the
pain behaviors were assessed by both von Frey and thermal
hyperalgesia tests for mechanical allodynia and thermal hyperal-
gesia, respectively. For comparison with Bushi-treated animals,
water was orally administered to sham-operated and SNL-
operated mice (i.e. Sham-Water and SNL-Water). Bushi
(300 mg/kg) was administered to mice right after SNL operation
and the pain behaviors were tested every day from 24 hr after the
final administration of chemicals (Fig. 1A). The concentration of
Bushi used in the present study was almost ED50 value. Chronic
administration of Bushi had no effect on both von Frey test
[23.361.9% (d0) v.s. 26.761.9% (d7), n=3] and the thermal
hyperalgesia test [9.960.1 sec (d0) v.s. 10.160.2 sec (d7), n=3] in
sham-operated mice. After SNL-operation, the pain behaviors in
both tests gradually increased till 7 days after the operation (d7),
when they were followed by constant and sustained pain behaviors
(d14–d21) (Fig. 1, B and C). Therefore, in this study, we defined
the former (i.e. 1–7 days after SNL operation) and the latter (i.e.
.7 days after SNL operation) as ‘early induction’ and ‘late
maintenance’ phases, respectively. In the Sham-Water group, no
pain behavior was observed. In the von Frey test, significant pain
behavior was observed at 3 days after the operation [25.563.3%
(d0) v.s. 48.965.5% (d3), n=9] and peaked at d14 (74.465.0%,
n=9). Similarly, in the thermal hyperalgesia test, the pain
behavior became significant at 3 days after the operation
[9.760.3 sec (d0) v.s. 7.960.6 sec (d3), n=9] and peaked at d14
(6.160.3 sec). Bushi was effective on the late maintenance phase
(i.e. from d7 to d21) of pain but appeared to be ineffective on the
early induction phase (i.e. from d0 to d7) (Fig. 1, B and C).
To examine whether Bushi is effective to only the late
maintenance phase but not to the early induction phase of pain,
the initiation of Bushi-administration was started 7 days after the
SNL operation (Fig. 2A, from b90t ob 914). At d7 (b90), SNL-
Water exhibited a dramatic increase in pain behaviors in both the
von Frey test [33.062.5% (d0) v.s. 72.562.5% (d7), n=12]
(Fig. 2B) and the thermal hyperalgesia test [10.160.2 sec (d0) v.s.
5.860.4 sec (d7), n=12] (Fig. 2C). These pain behaviors were
maintained for at least 35 days after the operation (72.565.0% in
the von Frey test and 5.460.5 sec in the thermal hyperalgesia test).
Bushi revealed analgesic effects against the late phase of
neuropathic pain (b97) (49.567.0% and 8.760.5 sec in the von
Frey and thermal hyperalgesia tests, respectively). A 14-day
administration of Bushi (b914) almost completely inhibited the
pain behaviors (34.563.5% and 8.960.5 sec in the von Frey and
thermal hyperalgesia tests, respectively). Thus, Bushi attenuated
the established maintenance phase but not the early induction
phase of neuropathic pain. Interestingly, even after Bushi
withdrawal, the analgesic effects lasted for at least another 2
weeks, although they were slightly reduced [55.862.7% (d28) and
55.863.3% (d35) in the von Frey test; and 7.660.6 sec (d28) and
7.260.3 sec (d35) in the thermal hyperalgesia test].
We next observed the morphological changes in spinal microglia
and astrocytes in the dorsal horn of the layer 1–2 at d21 in the late
maintenance phase of neuropathic pain. It is well known that this
spinal area is important for pain sensation because the primary
The Astrocyte-Targeted Therapy
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thus both the activated microglia and astrocytes observed in this area
after SNL operation could modulate the sensory transmission. In the
Sham-Water group, microglia were ramified with long branching
processes and small cellular bodies (Fig. 2D, upper panels, Sham-
Water), and the astrocytes did not exhibit any sign of activation
showing typical resting morphologies with thin processes and small
cell bodies (Fig. 2E, top panels, Sham-Water). The morphologies of
both microglia and astrocytes dramatically changed after the SNL
operation, i.e., microglia showed ameboid shapes with short and thick
processes (Fig. 2D, middle panels, SNL-Water), and astrocytes also
appeared hypertrophic with thick processes (Fig. 2E, middle panels,
SNL-Water).A 2-week administration of Bushi dramatically changed
the glial morphologies into the resting ones (Fig. 2D and E, bottom
panels, SNL-Bushi). We quantified both Iba1- and GFAP-immuno-
reactivities, showing the effect of Bushi. The intensity of the SNL-
induced increase in both Iba1- and GFAP-positive signals was
significantly decreased by 2-week administration of Bushi [Fig. 2F,
Iba1- (i) and GFAP-immunoreactivities (ii)]. It is well known that,
after nerve injury, extracellular signal-regulated kinase 1 and 2
(ERK1/2) are activated in spinal astrocytes, followed by the synthesis
ofseveralproinflammatory/nociceptivemediators,therebyleadingto
enhanced and prolonged pain [34]. In fact, the immunoreactivity of
phosphorylated-ERK1/2 (pERK1/2), a member of mitogen-activat-
ed protein kinases (MAPKs) was increased in GFAP-positive
astrocytes in our models (Fig. 2G, SNL-Water, middle panels). The
administration of Bushi dramatically decreased the pERK1/2 signals
in astrocytes (Fig. 2G, bottom panels).
To confirm that Bushi was not effective in the early induction
phase, it was administered to mice only in the early induction
phase. For this experiment, the administration of Bushi was
initiated 4 days before the SNL operation (Fig. 3A). Although 7-
day administration of Bushi was enough to reduce the pain
behaviors in the late maintenance phase (Fig. 2, B and C),
administration for 7 days or longer in the early induction phase
showed no analgesic effect [von Frey test; 24.063.7% (Sham-
Water), 70.065.7% (SNL-Water), and 64.065.3% (SNL-Bushi),
n=5] (Fig. 3B). Three days after SNL (d3), microglia showed
activated shapes, whereas the astrocytes looked normal (Fig. 3, C-
(i) and D-(i), SNL-Water). Unlike its effect on astrocytes, a 7-day
administration of Bushi (d3/b07) failed to inhibit microglial
activation (Fig. 3C-(i), SNL-Bushi). The significant augmentation
of Iba1-immunoreactivity in the ipsi-lateral side by SNL operation
remained at the same level at d3/b07 [Fig. 3C-(ii)]. We could not
observe any augmentation of GFAP-immunoreactivity by SNL
operation at d3 [Fig. 3D-(ii)].
Temporal relationship between spinal glial activation and
pain behaviors in neuropathic pain
To assess the temporal characteristic differences in the glial
contribution to the neuropathic pain, we pharmacologically
inhibited the activation of either microglia or astrocytes. The pain
behaviors were tested every day from 24 hr after the final
administration of chemicals. First, we selectively inhibited
microglial activation by intraperitoneal (i.p.) administration of
minocycline in SNL-mice. When minocycline administration was
Figure 1. Analgesic effects of Bushi on pain behaviors in Seltzer model mice. A. Time schedule of chronic administration of Bushi. Either
water or Bushi (300 mg/kg) administration (p.o., once-daily) was started right after SNL-operation. B, C. Pain behaviors induced by SNL, showing the
effects of Bushi. SNL-Water developed mechanical allodynia (B) and thermal hyperalgesia (C); there was no change in either pain behaviors in Sham-
Water. Bushi reduced both pain behaviors relatively late after the operation. d, days after SNL; b, days of Bushi administration. *p,0.05, **p,0.01
versus Sham-Water. #p,0.05, ##p,0.01 versus SNL-Water.
doi:10.1371/journal.pone.0023510.g001
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after SNL-operation (d14/m21) (Fig. 4A), the pain behaviors both
at the early induction and at the late maintenance phases were
significantly reduced (Fig. 4B and Table 1). We then investigated
the effect of minocycline on the activation of spinal glial cells, and
found that in this administration protocol, activation of astrocytes
as well as microglia at the late maintenance phase (d14/m21) was
inhibited (Fig. S1). However, when its administration was initiated
from the late maintenance phase [from 14 days after SNL-
operation (d14/m90) to 21 days after SNL-operation (d21/m97)]
(Fig. 4C), it no longer showed any analgesic effects (Fig. 4D,
Table 2). We again investigated the spinal glial morphology, and
found that in this administration protocol, unlike the behavioral
data, the administration of minocycline strongly inhibited the
activation of microglia at the late maintenance phase (d21/m97),
i.e., the ameboid shape was reversed to the ramified one, and
Iba1-immunoreactivity was decreased [Fig. 4, E, middle panels,
and G-(i), SNL-Minocycline/Ipsi]. It should be noted that even
when the microglial activation was reduced by minocycline,
astrocytic activation persisted in the late maintenance phase [Fig. 4,
F, middle panels, and G-(ii), SNL-Minocycline/Ipsi]. Next, we
inhibited the astrocytic activation by fluorocitrate, a well-known
metabolic inhibitor of astrocytes [23]. Fluorocitrate was adminis-
tered intrathecally every day from right after the SNL operation
(Fig. 5A). Fluorocitrate had no effect on the early induction phase
of pain (Fig. 5, B, C, d1–d7/f1–f7 and Table 3), but significantly
suppressed the late maintenance phase of pain (Fig. 5, B, C, d10–
d14/f10–f14 and Table 3). Importantly, fluorocitrate showed a
significant analgesic effect even when its administration was
initiated 14 days after the SNL operation (d14/f90), i.e., at the late
maintenance phase (Fig. 6, A–C, and Table 4). In addition,
fluorocitrate reversed the astrocytic activation, in association with
a decrease in the GFAP-immunoreactivity [Fig. 6, D and F-(i)] and
phosphorylation of ERK1/2 [Fig. 6G] at d21/f97 (administered
for 7 days from d14 to d21). It should be noted that fluorocitrate
had no effect on the activation of microglia in the early induction
phase, but did inhibit the activation of microglia in the late
maintenance phase, as did Bushi [Fig. 6, E, and F-(ii)] [23].
Direct effects of Bushi on cultured astrocytes and
microglia
Both IL-1b and IL-18 are well-known proinflammatory
cytokines that activate astrocytes causing chronic pain
[25,35,36]. They activate intracellular signaling molecules includ-
ing ERK1/2 [26] in astrocytes. When ERK1/2 is activated, it is
phosphorylated and translocated from the cytoplasm into the
nucleus [37]. We analyzed the effect of Bushi on the spatiotem-
poral behaviors of pERK1/2 in cultured spinal astrocytes.
Western blotting analysis showed that both IL-1b and IL-18
(10 ng/ml, 15 min) activated ERK1/2 (i.e. an increase in
pERK1/2) (Fig. 7, B and C). The increases in pERK1/2 proteins
by IL-1b or IL-18 were almost completely inhibited by Bushi
(0.1 mg/ml, 105 min pretreatment) [(DMEM, 100%; IL-1b,
152.969.6%; Bushi, 73.2620.8%; Bushi/IL-1b, 80.8611.0%)
and (DMEM, 100%; IL-18, 124.064.8%; Bushi, 93.665.1%;
Bushi/IL-18, 88.962.3%)]. To analyze the spatial behaviors of
pERK1/2, propidium iodide (PI), a fluorescent dye that binds to
DNA, was used for visualizing the nucleus. Without any
stimulation, only faint pERK1/2 signals were observed in the
entire cytoplasmic region. When astrocytes were stimulated with
IL-1b or IL-18 (10 ng/ml) for 15 min, strong pERK1/2 signals
were co-localized with the PI signals, suggesting the translocation
of pERK1/2 into the nucleus (Fig. 7D). A 2-hr treatment of Bushi
(0.1 mg/ml) dramatically inhibited the translocation of pERK1/2
(DMEM, 4.660.5%, n=8 wells; Bushi, 13.462.8%, n=9 wells;
IL-1b, 70.865.7%, n=9 wells; Bushi/IL-1b, 18.462.6%, n=9
wells; IL-18, 58.762.5%, n=8 wells; Bushi+IL-18, 18.462.6%,
n=8 wells) (Fig. 7E). Bushi did not inhibit the ATP-induced
phosphorylation of p38 and ERK1/2 in primary cultured cortical
microglia (Fig. 7, F–H).
Discussion
In the present study, we demonstrated that Bushi inhibited the
late maintenance phase of neuropathic pain without affecting the
early induction phase of pain, in association with the suppression
of astrocytic activation in the spinal cord. Although there is
accumulating evidence that the activation of both microglia and
astrocytes in the spinal cord is one of the key causes of neuropathic
pain [6,7,8], astrocytes have received only limited attention in
relation to pain. Here, however, we showed that the activation of
spinal astrocytes has a more important role in the maintenance
phase of neuropathic pain, and in addition and more importantly,
we found that Bushi inhibits the activation of astrocytes to
revealing analgesic effects against the chronic phase of neuropathic
pain. Many neuropathic pain patients suffer from sustained and
chronic pain for a long time and, therefore, it is of great
importance that Bushi inhibits the maintenance phase of pain.
A recent breakthrough in pain research is the discovery of
microglial involvement in the pathogenesis of neuropathic pain
[9]. Since this report, many investigators have focused on
microglia and made additional findings concerning the microg-
lia-related mechanisms of pain pathology. After peripheral nerve
injury, spinal microglia change their characteristic features and
increase various chemicals such as neuropeptides, cytokines,
chemokines, neurotransmitters, nucleotides and various receptors
such as P2X4 receptors, which in turn, lead to sustained changes in
the properties of the dorsal horn environment and the pain
sensation [3,9,38]. Among them, much of the information transfer
between activated microglia and neurons would be mediated by
microglia-derived brain derived neurotrophic factor (BDNF) [13].
Microglia release BDNF in response to ATP via the activation of
P2X4 receptors, which causes central sensitization by attenuating
Figure 2. Effects of Bushi on the late maintenance phase of neuropathic pain. A. Time schedule of chronic administration of Bushi.
Administration of water or Bushi (300 mg/kg) (p.o., once-daily) was started from d7 to d21 for 2 weeks, and withdrawn thereafter. B, C. Analgesic
effect of Bushi on late maintenance phase of mechanical allodynia (B) and thermal hyperalgesia (C). At d7, both mechanical allodynia and thermal
hyperalgesia were observed in SNL-Water and SNL-Bushi. These pain behaviors were maintained at least until d35 in SNL-Water. Bushi reduced the
pain behaviors at d14/b97 and d21/b914, and even at d35 (2 weeks after withdrawal of Bushi). D, E. Immunohistochemical analysis of spinal microglia
(D) and astrocytes (E). In SNL-Water, both Iba1- (upper panels) and GFAP- (lower panels) positive immunoreactivities were increased on d21 within
the ipsilateral side of the dorsal horn (layer 1–2 area). A 2-week Bushi administration markedly suppressed both immunoreactivities. F. Semi-
quantitative analysis of Iba1- (i) and GFAP- (ii) expression. Data indicate the relative mean immunofluorescence intensity of a single cell (n=10).
G. Double immunostaining of dorsal spinal cord with anti-pERK1/2 and -GFAP antibodies. In SNL-Water, pERK1/2-immunoreactivities (red) were
increased in the ipsilateral side of the dorsal horn (d21), and were co-localized with the GFAP-signals (green). Bushi (2-week administration) also
inhibited pERK1/2 in astrocytes. d, days after SNL; b0, days of Bushi administration. *p,0.05, **p,0.01 versus Sham-Water. #p,0.05, ##p,0.01
versus SNL-Water. $p,0.05, $$p,0.01 versus SNL-Water Contra. {p,0.05, {{p,0.01 versus SNL-Water Ipsi. Scale bars: 20 mm.
doi:10.1371/journal.pone.0023510.g002
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PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23510Figure 3. Effects of Bushi on the induction phase (early phase) of neuropathic pain. A. Time schedule of chronic administration of Bushi.
Either water or Bushi (300 mg/kg) administration (p.o., once-daily) was started from 2d4 to d3. B. Mechanical allodynia induced by SNL at d3. A 7-day
administration of Bushi was not effective on the mechanical allodynia at d3/b07. C, D. Effects of Bushi on the morphological change of spinal
The Astrocyte-Targeted Therapy
PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23510microglia (C) and astrocytes (D) in the early induction phase (i). Semi-quantitative analysis of Iba1- and GFAP-expression (ii). Data indicate the relative
mean immunofluorescence intensity of a single cell (n=10). Bushi did not suppress the increase in Iba1-immunoreactivity by SNL within the
ipsilateral side of the dorsal horn (i.e. layer 1–2 area) at d3 (C). The elevation of GFAP-immunoreactivity had not occurred at d3 (D). d, days after SNL;
b9, days of Bushi administration. **p,0.01 versus Sham-Water. $$p,0.01 versus SNL-Water Contra. Scale bars: 100 mm.
doi:10.1371/journal.pone.0023510.g003
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pathic pain. Thus, microglia are considered to be a potential target
for neuropathic pain therapy as well as for understanding its
pathogenesis. In the present Seltzer model mice, the time-course of
the pain behaviors consisted of two phases, i.e., the early induction
phase (,7 days after SNL) and the sustained maintenance phase
(.7 days after SNL). Microglia had a pivotal role in the initiation
of neuropathic pain in the early induction phase, and when their
initial activation was inhibited by minocycline, the pain behavior
was attenuated (Fig. 4B and Table 1). However, the analgesic
effect of minocycline is time-dependent, i.e., it showed analgesic
effects when administered at the early induction phase. When
administration of minocycline was started at the late maintenance
phase, it no longer showed any analgesic effects (Fig. 4, C and D).
It should be noted that, in this administration protocol,
minocycline did inhibit microglial activation but did not attenuate
the pain behaviors at the late maintenance phase [Fig. 4, E and G-
(i)]. These findings strongly suggest that activation of spinal
microglia is no longer responsible for the late maintenance phase
of neuropathic pain and that factors other than microglial
activation should be involved in the later stage of neuropathic
pain in this model.
Unlike minocycline, Bushi did not attenuate the early induction
phase but, instead, it dramatically inhibited the late maintenance
phase of pain, which suggests that Bushi, acting on minocycline-
insensitive molecules, exerted its analgesic effects presumably via
microglia-independent mechanisms. Recently, it has been report-
ed that the activation of astrocytes is also involved in neuropathic
pain and, interestingly, its involvement seemed to contribute to
rather the chronic phase of pain [39,40]. Similar to these reports,
our present results showed that the activations of microglia and
astrocytes were mainly observed in the early induction phase
(Fig. 3C) and the late maintenance phase of neuropathic pain
(Fig. 2, E, F-(ii), G, 4, F, G-(ii), 6, D, F-(i) and G), respectively.
Bushi did not inhibit the activation of microglia in the early
induction phase (Fig. 3C) but inhibited that of astrocytes in the late
maintenance phase, and exerted analgesic effect against the late
maintenance phase of neuropathic pain (Fig. 2, B–E). Similarly,
fluorocitrate, a selective inhibitor of astrocytic activation [23],
exerted analgesic effects against the late maintenance phase but
not the early induction phase (Fig. 5, B and C). These findings
strongly suggest that the activation of astrocytes is responsible for
the late maintenance phase of neuropathic pain and that Bushi
acts on astrocytes to exert its analgesic effect. However, when
chronic administration of minocycline was initiated at the early
induction phase, it inhibited pain behaviors even at the late
maintenance phase as well as those at the early induction phase. In
this administration protocol, minocycline also inhibited activation
of spinal astrocytes at the late maintenance phases (Fig. S1),
suggesting that microglial activation at the early induction phase
should be a trigger for subsequent activation of astrocytes in the
late maintenance phase in this model. Thus, activation of
astrocytes is still important event for the maintenance phase of
pain.
Although Bushi had no effect on microglial activation in the
early induction phase (Fig. 3C), it suppressed the activation in the
late maintenance phase of pain (Fig. 2, D and F-(i)). This finding
raises the possibility that Bushi might also act on microglia and
inhibit thier activation to reveal analgesic effect. However, we also
found that (1) Bushi did not inhibit the ATP-induced activation
(phosphorylation of p38 and ERK1/2) in primary microglia in vitro
(Fig. 7, F–H), (2) fluorocitrate, an astrocytic inhibitor, also reduced
the activation of microglia in the late maintenance phase [Fig. 6, E
and F-(ii)]. All these findings suggest that Bushi secondarily
suppresses the activation of microglia via the deactivation of
astrocytes in the late maintenance phase.
The analgesic effect of Bushi is very interesting because (1) it was
effective on established neuropathic pain (Fig. 2, B and C), (2) its
analgesic effect was observed even when it was withdrawn (Fig. 2,
B and C). Astrocytes are highly plastic but their changes are often
Figure 4. Role of microglial activation at the early induction phase and late maintenance phase of neuropathic pain. A. Time schedule
of chronic administration of minocycline from the early induction phase to the late maintenance phase. Pain behavior was assessed by von Frey test
at the time points indicated by arrowheads. B. Mechanical allodynia increased with time up to d7 and maintained thereafter in SNL-Water.
Minocycline reduced the pain behavior both at the induction and maintenance phases. C. Time schedule of chronic administration of minocycline at
the late maintenance phase. D. At the late maintenance phase, the established neuropathic pain by SNL was not decreased by minocycline. E, F.
Morphological change of Iba1-positive spinal microglia (E) and augmentation of Iba1-immunoreactivity [G-(i)] by SNL were controlled by minocycline
at the late maintenance phase. Minocycline had no effect on the morphological changes of GFAP-positive spinal astrocytes (F) and GFAP-
immunoreactivity [G-(ii)]. d, days after SNL; m and m9, days of minocycline administration. *p,0.05, **p,0.01 versus Sham-Vehicle. ##p,0.01 versus
SNL-Vehicle. $$p,0.01 versus SNL-MC (minocycline) Contra. {{p,0.01 versus SNL-MC Ipsi. Scale bars: 20 mm.
doi:10.1371/journal.pone.0023510.g004
Table 1. Effect of intraperitoneal administration of minocycline on mechanical allodynia (Fig. 4B).
von Frey test ,0.166 g. % of max score (%)
d0 (m7) d1 (m8) d3 (m10) d5 (m12) d7 (m14) d10 (m17) d14 (m21)
Sham-Vehicle 19.061.8 23.064.4 19.061.9 24.062.9 20.062.2 23.064.1 29.062.9
SNL-Vehicle 20.062.9 52.564.4** 74.066.0** 78.361.7** 81.761.7** 83.363.3** 83.361.7**






To assess mechanical allodynia, von Frey test was performed. The number of paw withdrawal times in response to a 0.166 g von Frey filament was counted and scored
as followed; One trial involved 10 applications of filaments every 3 or 4 s, each of which was scored as 0, 1 or 2 as described in the methods section. The trial was




d, days after SNL-operation; m, days of minocycline administration.
doi:10.1371/journal.pone.0023510.t001
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inhibition of their activation-feedforward loop [26]. Thus, Bushi
may regulate reversible activation, and control the deactivation of
astrocytes, thereby leading to its analgesic effect. The ‘‘activation’’
of astrocytes is a very ambiguous word that involves many types of
astrocytic events or conditions and therefore the deactivation of
astrocytes would also involve the inhibition of many molecules in
astrocytes. In general, the activation of astrocytes is defined
immunohistochemically as hypertrophic morphology with thick
processes and increased GFAP-positive signals. Although upregu-
lated GFAP itself might affect the astrocytic function [41], it is
believed that many other events seen in spinal nerve injury,
including the phosphorylation of MAP kinases [34] and increases
in pro-inflammatory cytokines and chemokines [42,43], would be
more important for the pain sensation [44]. So far, however, it has
remained unknown which astrocytic molecules are responsible for
the maintenance phase of pain, and which molecule(s) ‘‘Bushi’’
inhibits to reveal its analgesic effects. With regard to pain-related
astrocytic molecules, it has been reported that astrocytes could
directly modulate the neuronal activity by releasing inflammatory
cytokines including IL-1b in a chronic pain state via N-methyl-D-
aspartate (NMDA) receptor-mediated mechanisms [45,46]. Thus,
such astrocytic pro-inflammatory cytokines would be among the
most probable molecules that induce the maintenance phase of
pain. With regard to the target molecule(s) of Bushi, we showed
that one of the ERK1/2-mediated signaling molecules was
involved. The activation of ERK1/2 by SNL results in the
synthesis of several proinflammatory/nociceptive mediators,
thereby leading to enhanced and prolonged neuropathic pain
[34,47]. In the present study, the immunoreactivity of pERK1/2
was increased by SNL in GFAP-positive spinal astrocytes (Fig. 2G,
SNL-Water, middle panels), and was reversed by the administra-
Table 2. Effect of intraperitoneal administration of
minocycline on mechanical allodynia in the maintenance
phase (Fig. 2D).
von Frey test ,0.166 g. % of max score (%)
d14 (m90) d17 (m93) d21 (m97)
Sham-Vehicle 15.060.0 16.761.2 20.062.0
SNL-Vehicle 80.064.1 81.766.6** 83.062.3**
SNL-Minocycline 78.366.5 63.364.2* 75.365.4**
To assess mechanical allodynia, von Frey test was performed as described in
table 1. Data show mean 6 s.e.m. (n=3).
*p,0.05,
**p,0.01 versus Sham-Vehicle.
d, days after SNL operation; m9, days of minocycline administration.
doi:10.1371/journal.pone.0023510.t002
Figure 5. Effect of fluorocitrate on pain behaviors in the early induction phase and the late maintenance phase of neuropathic pain.
A. Time schedule of chronic administration of fluorocitrate. Either vehicle or fluorocitrate (100 fmol/mouse) administration (i.t., once-daily) was started
right after the SNL operation. B, C. Mechanical allodynia and thermal hyperalgesia were assessed from the early induction phase to the late
maintenance phase. SNL-Vehicle developed mechanical allodynia (B) and thermal hyperalgesia (C); there was no change in the pain behaviors in
Sham-Vehicle. Fluorocitrate reduced both pain behaviors only at the late maintenance phase, but was not effective at the early induction phase, as
was the case with Bushi. d, days after SNL; f, days of fluorocitrate administration. *p,0.05, **p,0.01 versus Sham-Vehicle. ##p,0.01 versus SNL-
Vehicle. Scale bars: 20 mm.
doi:10.1371/journal.pone.0023510.g005
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activation and translocation of pERK1/2 induced by either IL-1b
or IL-18, both of which are released from microglia [25,35,36],
were also reversed by Bushi in cultured astrocytes in vitro (Fig. 7, B–
E). These results suggest that Bushi acts on astrocytes directly and
suppresses astrocytic activation, presumably via the inhibition of
ERK1/2-related signals.
The time-courses in analgesic effects of Bushi on von Frey and
thermal hyperalgesia tests were different, and von Frey test looks
more sensitive to Bushi (Fig. 1, B and C). Although both tests are
well-used indexes for neuropathic pain, mechanisms underlying
mechanical allodynia and thermal hyperalgesia are not necessarily
same, and therefore, distinct molecules are involved in the pain
behaviors. For example, NMDA receptor is more important to
induce thermal hyperalgesia than mechanical allodynia because
MK801, a blocker of NMDA receptors, is more effective to
thermal hyperalgesia than allodynia [48]. Thus, molecules
involved in mechanical allodynia might be more sensitive to
Bushi, but further investigation is required to clarify this. In
addition, we must await further study to identify the pain-related
molecules that are activated and inhibited by SNL and Bushi in
astrocytes, respectively. Judging from previous studies, multiple
molecules in astrocytes appear to be involved in the pain and be
the targets of Bushi [44]. If this is the case, the multi-target therapy
by Bushi might be a useful clinical strategy for the persistent
neuropathic pain. Although fluorocitrate also showed an analgesic
effect against the late maintenance phase of pain, it should be
noted that unlike fluorocitrate, Bushi is appropriate for human
application because it has already been used clinically for several
diseases, and has not been reported to cause serious side effects as
flurocitrate and its related chemicals did in animal models of
neuropathic pain [49,50].
Taken together, we demonstrated that Bushi acts on spinal
astrocytes to reverse their activation, thereby leading to inhibition
of the persistent late maintenance phase of neuropathic pain. A
minute investigation of the molecular mechanisms underlying the
Bushi-induced deactivation of astrocytes as well as its analgesic




All procedures were performed in accordance with the
‘‘Guiding Principles in the Care and Use of Animals in the Field
of Physiologic Sciences’’ published by the Physiologic Society of
Japan [51] and with the previous approval of the Animal Care
Committee of Yamanashi University (Chuo, Yamanashi, Japan).
Using 8 week-old male ICR mice (Japan SLC, Shizuoka, Japan),
we produced a partial sciatic nerve injury model by tying a tight
ligature with an 8–0 silk suture around approximately 1/3–1/2 the
diameter of the sciatic nerve located on the right-hand side
(ipsilateral side). This method is similar to the approach described
in rats by [52] and in mice by [53]. In sham-operated mice, the
nerve was exposed without ligation.
Drug treatment
We used clinically available Bushi (TJ-3023, Tsumura Co. Ltd.,
Japan), a processed aconiti tuber whose quality is strictly controlled
by a 3D-HPLC analysis. Bushi was suspended and diluted with
water for oral administration (30 mg/ml, 300 mg/kg, approxi-
mately 0.3–0.4 ml/mouse). Fluorocitrate (Sigma-Aldrich), an
inhibitor of astrocytic activation, was administered intrathecally
(100 fmol/5 ml/mouse). This is within the safe range for the
selective effect of fluorocitrate on astrocytes without neuronal
damage [23]. Minocycline (Sigma-Aldrich), an inhibitor of
microglial activation, was administered intraperitoneally (30 mg/
kg, approximately 0.3–0.4 ml/mouse). The dosage of minocycline
used in the present study was based on a previous report [23].
Behavioral analysis
On each testing day, the mice were brought into the behavior
room 1 hr before the test session to allow them to habituate to the
environment. Thermal hyperalgesia was assessed sensitivity to
thermal stimulation. The hind paws of the mice were tested
individually using a radiant thermal stimulus apparatus (model 33,
Analgesia Meter; IITC/Life Science Instruments, Woodland Hills,
CA, USA). The latency of the paw withdrawal after the thermal
stimulus was determined as the average of four measurements per
Table 3. Effect of intrathecal administration of fluorocitrate on mechanical allodynia and thermal hyperalgesia in the induction
phase (Fig. 5, B and C).
von Frey test ,0.166 g. % of max score (%)
d0 (f0) d1 (f1) d3 (f3) d5 (f5) d7 (f7) d10 (f10) d14 (f14)
Sham-Vehicle 33.361.2 15.064.1 26.761.2 23.363.1 26.765.1 21.763.1 25.060.0
SNL-Vehicle 32.061.7 53.061.7** 78.062.9** 86.062.4** 87.061.3** 89.062.4** 85.061.4**
SNL-Fluorocitrate 31.061.5 45.063.1* 68.063.6** 79.062.7** 70.062.6** 39.061.5
## 35.061.8
##
Thermal hyperalgesia test Withdrawal latensy (sec)
d0 (f0) d1 (f1) d3 (f3) d5 (f5) d7 (f7) d10 (f10) d14 (f14)
Sham-Vehicle 10.560.9 10.460.2 10.260.2 10.261.0 10.061.1 10.660.8 10.160.6
SNL-Vehicle 10.260.1 6.560.1** 4.860.1** 5.160.2** 5.260.4** 4.760.2** 4.860.2**
SNL-Fluorocitrate 10.460.2 7.960.6* 4.560.2** 5.360.1** 5.760.2** 7.460.2**
,## 8.260.3
##
For mechanical allodynia, von Frey test was performed as described in table 1. Thermal hyperalgesia test was evaluated by the latency of paw withdrawal after the




d, days after SNL operation; f, days of fluorocitrate administration.
doi:10.1371/journal.pone.0023510.t003
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intensity of the thermal stimulus was adjusted to achieve an average
baseline paw withdrawal latency of approximately 9–11 sec in naive
mice.Only quickhind paw movements (eitherwith or without licking
of hind paws) away from the stimulus were considered to be
withdrawal responses. Mechanical allodynia was quantified by
measuring the hind paw withdrawal response sensitivity using von
Freyfilaments.VonFreyfilamentswereappliedtotheplantarsurface
of the hind paw. The paw withdrawal in response to the tactile
stimulus was evaluated by scoring as follows: 0, no response; 1, a
withdrawal response away from the stimulus with slight flinching
and/or licking; 2, an intense withdrawal response away from the
stimulus with brisk flinching and/or licking [54]. One trial involved
10applicationsoffilamentsevery3or4 sec,each of which wasscored
as 0, 1 or 2. The trial was evaluated based on a total score of 0–20 at
the culmination (% of max score).
Immunohistochemistry
After perfusion, the lumbar spinal cord was postfixed in 4%
paraformaldehyde for 24 hr, and then permeated with 20%
sucrose in 0.1 M PBS for 24 hr and 30% sucrose in 0.1 M PBS for
48 hr at 4uC. Lumbar spinal cord segments were frozen in an
embedding compound (Sakura Finetek, Tokyo, Japan) on dry ice.
Frozen spinal segments were cut with a cryostat (Leica CM 1100;
Leica, Wetzlar, Germany) at a thickness of 30 mm and collected in
PBS at 4uC to be processed immunohistochemically as free-
floating sections. The sections were incubated overnight at 4uC
with primary antibodies: mouse anti-GFAP (1:2000; Millipore),
rabbit anti-Iba1 (1:2000; a kind gift from Dr. S. Kohsaka, National
Institute of Neurosciences, Tokyo, Japan) and rabbit anti-pERK1/
2 (1:500; Cell Signaling Technology). The sections were washed
six times with 0.01 M PBS (10 min each) and then incubated for
3 hr at room temperature with the secondary antibody: Alexa488-
and Alexa546-conjugated mouse- and rabbit-IgGs (Invitrogen).
Immunohistochemical images were obtained using a confocal laser
microscope (Fluoview1000; Olympus, Tokyo, Japan) and digital
images were captured with Fluoview1000 (Olympus). For the
comparison of double-stained patterns, images were processed
using Photoshop 5 (Adobe System, Mountain View, CA).
Cell culture
The culture of spinal astrocytes and cortical microglia were
prepared as described [19] with minor modifications. Spinal
astrocytes and cortical microglia were dissected from neonatal
Wistar rats. To purify astrocytes (GFAP-positive cells) from the
mixture of spinal cord cultures, the cells were subjected to 24 hr of
continuous shaking 10–14 days after plating to remove detached
cells. For the Western blotting analysis, cells were seeded on 6-well
cell culture plates (greiner bio-one, Tokyo, Japan) at a density of
1610
5 cells/well. For the immunocytochemistry, cells were seeded




After IL-1b or IL-18-stimulation, cells were lysed and the lysates
were resolved with 10% SDS-PAGE gels and transferred to PVDF
membranes. The membranes were blocked for 1 hr in Tris-
buffered saline containing 0.1% Tween-20 (TBS/T) and 5%
bovine serum albumin (BSA) at room temperature. Then the
membranes were incubated with the primary antibody: rabbit
anti-pERK1/2 (1:5000; Cell Signaling Technology) and rabbit
anti-pp38 (1:5000; Cell Signaling Technology) diluted with Can
Figure 6. Role of astrocytic activation at the early induction phase and late maintenance phase of neuropathic pain. A. Time schedule
of chronic administration of fluorocitrate, evaluating its effect on the late maintenance phase of neuropathic pain. Vehicle and fluorocitrate
administration was started from d14 to d28 for 2 weeks. B, C. Analgesic effects of fluorocitrate on mechanical allodynia (B) and thermal hyperalgesia
(C) in the late maintenance phase. Fluorocitrate revealed analgesic effects when it was administered in the late maintenance phase (from d15/f91t o
d28/f914). D–F. Immunohistochemical analysis of spinal glial cells, showing the effects of fluorocitrate. Fluorocitrate reduced the morphological
changes of GFAP-positive spinal astrocytes (D, lower panels) at d21/f97 and the augmentation of GFAP- immunoreactivity [F-(i)], which was associated
with the inhibition of pERK1/2 (G, lower panels). Fluorocitrate also reduced the morphological changes of Iba1-positive spinal microglia (E, lower
pannels) and augmentation of Iba1-immunoreactivity [F-(ii)] at d21/f97, as did Bushi. d, days after SNL; f9, days of fluorocitrate administration.
**p,0.01 versus Sham-Vehicle. ##p,0.01 versus SNL-Vehicle. $$p,0.01 SNL-Water Ipsi versus SNL-FC (fluorocitrate) Ipsi. Scale bars: 20 mm.
doi:10.1371/journal.pone.0023510.g006
Table 4. Effect of intrathecal administration of fluorocitrate on mechanical allodynia and thermal hyperalgesia in the maintenance
phase (Fig. 6, B and C).
von Frey test ,0.166 g. % of max score (%)
d0 d14 (f90) d15 (f91) d17 (f93) d21 (f97) d28 (f914)
Sham-Vehicle 33.361.4 23.164.1 30.065.0 21.361.1 26.761.4 25.060.6
SNL-Vehicle 31.660.4 79.760.6** 73.961.4** 78.160.6** 81.761.0** 83.361.6**




Thermal hyperalgesia test Withdrawal latensy (sec)
d0 d14 (f90) d15 (f91) d17 (f93) d21 (f97) d28 (f914)
SNL-Vehicle 10.560.1 5.860.1** 6.260.4** 5.360.2** 5.860.2** 6.360.5**









d, days after SNL operation; f9, days of fluorocitrate administration.
doi:10.1371/journal.pone.0023510.t004
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solution, overnight at 4uC. After three washes with TBS/T, the
membranes were incubated with horseradish peroxidase-conju-
gated anti-rabbit antibody (1:20000; Amersham Pharmacia
Biotech Inc., Piscataway, NJ, USA) diluted with Can Get SignalH
solution 2 (TOYOBO) for 1 hr at room temperature. The
membranes were washed with TBS/T three times, and the
proteins were visualized by chemiluminescence. To detect total
ERK1/2 and p38, aliquots of the same sample were resolved with
SDS-PAGE gels, transferred to PVDF membranes in the same
conditions and exposed to rabbit anti-total ERK1/2 antibody
(1:5000; Cell Signaling Technology) and rabbit anti-total p38
antibody (1:5000; Cell Signaling Technology), respectively. To
quantify the intensity of the each bands, we used ImageJ (http://
rsb.info.nih.gov/ij/). Each bands were selected by rectangular
selection. Then, we selected Analyze-Gels-Select First Lane from the
menu bar. The area corresponding to each band was measured
using the Wand (tracing) tool from the tool bar.
Immunocytochemistry
After each treatment, the cells were fixed for 30 min at room
temperature in 99% methanol. The fixed cells were permeabilized
with PBS containing 0.1% Triton X-100 for 15 min at room
temperature and then incubated with the polyclonal rabbit anti-
pERK1/2 antibody for 24 hr at 4uC. After washing, the cells were
incubated with the appropriate secondary antibody conjugated to
Alexa 488 and propidium iodide (PI), a DNA biding dye, for 1 hr
at room temperature. The images were obtained using a confocal
laser microscope and digital images were captured with Fluo-
view1000. For the comparison of double-stained patterns, images
were processed using Photoshop 5.
Statistical Analysis
All results were expressed as mean 6 SEM, together with the
number of animals or cultured-wells. All data were analyzed using
analyses of variance (ANOVA) performed with Scheffe multiple
comparison tests. A p value less than 0.05 was considered to be
statistically significant.
Supporting Information
Figure S1 Suppression of microglial activation by minocycline at
the erarly induction phase resulted in inhibition of subsequent
astrocytic activation at the late maintenance phase. Immunohis-
tochemical analysis of microglia (Iba-1-positive signals) (A, B) and
astrocytes (GFAP-positive signals) (C, D), showing effect of chronic
administration of minocycline (30 mg/kg, p.i.). The administra-
tion protocol was same as Fig. 4A (from 2d7 to d14). Rectangulars
in A and C were expanded and shown as high magnification
images in the corresponding lower pannels. Suppression of
microglial activation (A) resulted in inhibition of subsequent
astrocytic activation at the late maintenance phase (E; SNL-
Minocycline (d14/m21), Ipsi), which was summarized in B
(microglia) and D (astrocytes). $$p,0.01 versus Sham-Vehicle
Contra. {{ ,0.01 versus Sham-Vehicle Ipsi. Scale bars: 50 mm.
(EPS)
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